Screening for prostate cancer: Current recommendations

Urologic Clinics of North America

Volumn 31, Issue 2, 2004, Pages 219-226

  Wilson, Shandra S ^a   Crawford, E David ^b  

^a Anschutz Cancer Center   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; HYDROCHLOROTHIAZIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; AUTOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN; HYPERTENSION; LETHALITY; LIVER TRANSPLANTATION; MAMMOGRAPHY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; SCANDINAVIA; SCORING SYSTEM; SCREENING TEST; SMOKING CESSATION;

EID: 2342655778     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2004.01.002     Document Type: Review

References (67)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics 2003. CA Cancer J Clin. 53:2003;5-26
2. Brawer M.K. Screening for prostate cancer. Semin Surg Oncol. 18:2000;29
3. Kerlikowski K.M., Grady D.G., Barclay J., et al. Positive predictive value of screening mammography by age and family. JAMA. 270:1993;2444-2450
4. Brawer M.K. Prostate-specific antigen: current status. CA Cancer J Clin. 49:(5):1999;264-281
5. Hakama M., Stenman U., Aromaa A., et al. Validity of the prostate specific antigen tests for prostate cancer screening: follow-up study with a bank of 21, 000 sera in Finland. J Urol. 166:(6):2001;2189-2192
6. Helzlsouer K.J., Newby J., Comstock G.W., et al. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. Cancer Epidemiol Biomarkers Prev. 1:1992;537-540
7. Partin A.W., Kattan M.W., Subong E.N.P., et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA. 277:(18):1997;1445-1451
8. Thompson I.M., Goodman P.H., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 349:(3):2003;211-220
9. Stamey T.A., Johnstone I.M., McNeal J.E., et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol. 167:(1):2002;103-111
10. Hammerer P.G., McNeal J.E., Stamey T.A. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol. 153:(1):1995;111-114
11. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA. 273:(4):1995;289-294
12. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6, 630 men. J Urol. 151:1994;1283-1290
13. Catalona W.J., Antenor J.A., Roehl K.A., et al. Screening for prostate cancer in high risk populations. J Urol. 168:(5):2002;1980-1984
14. Mäkinen T., Tammela T.L.J., Stenman U.-H., et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol. 20:(11):2002;2658-2662
15. Surveillance, epidemiology, and end results (SEER) program public use CD-ROM (1973-94), National Cancer Institute, DCPC, surveillance program, cancer statistics branch. Released May 1997. J Urol. 168:(2):2002;483
16. Mettlin C., Littrup P.J., Kane R.A., et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data form the American Cancer Society National Prostate Cancer Detection Project. Cancer. 74:1994;1615
17. Punglia R.S., D'Amico A.V., Catalona W.J., et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 349:(4):2003;225-242
18. Liu S., Lee I.M., Linson P., et al. A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidemiol. 29:(1):2000;29-35
19. Okegawa T., Kino M., Ohata M., et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1-10ng/ml. Int J Urol. 10:(4):2003;201-206
20. Kahn M.A., Parin A.W., Rittenhouse H.G., et al. Evaluation of prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0-10.0ng/ml. J Urol. 170:(3):2003;723-726
21. Martinez M., Narvarro S., Medina P., et al. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer. Eur Urol. 43:(6):2003;609-614
22. Haese A., et al. The role for human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate. 54:2003;181-186
23. Banez L.L., Prasanna P., Sun L., et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol. 170:(2 Part 1):2003;442-446
24. Keetch D.W., Catalona W.J., Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 151:1994;1571-1574
25. Levine M.A., Ittman M., Mclamed J., et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 159:1998;471-476
26. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 95:(12):2003;868-878
27. Stamey T.A., Donaldson A.N., et al. Histological and clinical findings in the United States treated with radical retropubic prostatectomy; histologic significance of annual changes. J Urol. 160:1998;2412-2417
28. Holmberg L., Bill-Axelson A., Helgessen F., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 347:2002;781-789
29. Whitmore W.F., et al. Consensus development conference on the management of clinically localized prostate cancer. Overview: historical and contemporary. Natl Cancer Inst Monogr. 7:1988;7-11
30. Merrill R.M., Potosky A.L., Feuer E.J. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst. 88:1996;1683-1685
31. Breslow N., Chang C.W., Dhom G., et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer. 20:1977;680
32. Schroder F.H., van der Cruijsen-Koeter I., de Koning J.H., et al. Prostate cancer detection at low prostate specific antigen. J Urol. 163:2000;806-812
33. Etzioni R., Legler J., Feuer E., et al. Cancer surveillance series: interpreting trends in prostate cancer - part III: qualifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 91:1999;1033-1039
34. Thompson I, Presti J. Recent advances in the management of prostate cancer. Faculty Update, University of Texas at San Antonio, 2003.
35. Epstien J., Walsh P., Carmichael M., et al. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 271:1994;368-374
36. Andriole G. Prostate cancer screening. Presented at the National Urology Oncology Update. Long Beach, California, March 2003.
37. Fowler F.J. Jr., Barry M.J., Lu-Yao G., et al. Patient-reported complications and follow-up treatment after radical prostatectomy: the national medicare experience 1988-1990 (updated June 1993). Urology. 42:(6):1993;622-629
38. Catalona W., Antenor J.V., Roehl K.A. Screening for prostate cancer in high risk populations. J Urol. 168:(5):2002;1980-1984
39. Thompson I.M., Middleton R.G., Optenberg S.A. Have complications rates decreased after treatment for localized prostate cancer? J Urol. 162:1999;107-112
40. Crawford ED, Chia D, Andriole GL, et al. PSA changes as related to the initial PSA: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Presented at American Urological Association, Atlanta, Georgia, 2001.
41. Crawford ED, Pinsky PF, Chia D, et al. PSA changes as related to the initial PSA: data from the Prostate, Lung, Colorectal and Ovarian Cancer screening trial. JAMA, in press.
42. Crocetti E., Ciatto S., Zappa M. Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy. [letter] J Natl Cancer Inst. 93:2001;876-877
43. Oliver S.E., Gunell D., Donovan J.L. Comparison of trends in prostate cancer mortality in England and Wales and the USA. Lancet. 355:2000;1788-1789
44. Perron L., Morre L., Bairate I., et al. PSA screening and prostate cancer mortality. Can Med Assoc J. 166:(5):2002;586-591
45. Makinen T., Tammela T.L.J., Hakama M., et al. Tumor characteristics in a populations-based prostate cancer screening trial with prostate specific antigen. Clin Cancer Res. 9:2003;2435
46. Coley C.M., Barry M.J., Fleming C., et al. Early detection of prostate cancer: I. Prior probability and effectiveness of tests. Ann Intern Med. 126:1997;394-406
47. Lu-Yao G., Albertsen P.C., Stanford J.L., et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 325:(7367):2002;740-750
48. Coldman A.J., Phillips N., Pickles T.A. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. Can Med Assoc J. 168:(1):2003;31
49. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 38:(2):1999;83-91
50. Meyer F., Moore L., Bairati I., et al. Downward trend in prostate cancer mortality in Quebec and Canada. J Urol. 161:1999;1889
51. Oliver S.E., May M.T., Gunnell D. International trends in prostate-cancer mortality in the PSA ERA. Int J Cancer. 92:2001;893-898
52. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 58:(3):2001;417-424
53. Roberts R.O., Bergstralh E.J., Katusic S.K., et al. Decline in prostate cancer mortality from 1980 to 1997, an update on incidence trends in Omsted County, Minnesota. J Urol. 161:1999;529-533
54. Shala D.E. Cancer death rate decline for the first time ever in the 1990s [press release]. 1996;National Cancer Institute, Bethesda, MD
55. Gronberg H., Damber J., Jonsson H., et al. Patient age as a prognostic factor in prostate cancer. J Urol. 152:1994;892-895
56. Quinn M., Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality Part I: international comparisons. Br J Urol. 90:(2):2002;162-173
57. Ries L.A.G., Eisner M.P., Kosary C.L., et al. SEER cancer statistics reviewed 1973-1999. 2002;National Cancer Institute, Bethesda, Maryland
58. Gohagan J.K., Prorok P.C., Hayes R.B., et al. The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 21:(Suppl 6):2000;251S-272S
59. Auvinen A., Rietbergen J.B., Denis L.J., et al. Prospective evaluation plan for randomized trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen. 3:1996;97-104
60. McLaughlin A.P., Saltzstein S.L., McCullough D.L., et al. Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol. 115:1976;89-94
61. Thompson I.M., Ernst J.J., Gangai M.P., et al. Adenocarcinoma of the prostate: results of routine urological screening. J Urol. 132:1984;690-692
62. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate specific antigen. JAMA. 276:(16):1996;1309-1315
63. Jhaveri F.M., Klien E.A., Kupelian P.A., et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 17:(10):1999;3167-3172
64. Gustafsson O., Norming U., Almgard L.E., et al. Diagnostic methods in the detection of prostate cancer. A study of a randomly selected population of 3, 000 men. J Urol. 148:1992;1827
65. Aus G., Hugosson J. Fifteen-year survival with prostate cancer in Sweden. JAMA. 278:1997;205-206
66. Aus G. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol Suppl. 167:1994;1-41
67. Lu-Yao G.L., Yao S.L. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet. 349:1997;906-910